Cargando…
Hypercalcemia and hypercalciuria during denosumab treatment in children with osteogenesis imperfecta type VI
Children with osteogenesis imperfecta (OI) type VI often have high fracture rates despite the current standard treatment with bisphosphonates. Subcutaneous injections of denosumab have been proposed as an alternative treatment approach, but safety data on denosumab in children are limited. Here we d...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
International Society of Musculoskeletal and Neuronal Interactions
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881132/ https://www.ncbi.nlm.nih.gov/pubmed/29504582 |